澳门在线赌城娱乐 divests rights to 瑞宁得 和 Casodex in Europe 和 certain additional countries

2019年12月20日07:00 GMT
 

Sale 给juvis制药公司 supports 澳门在线赌城娱乐’s strategy
of focusing on pipeline of new medicines
 

澳门在线赌城娱乐 today announced that it has agreed to sell the commercial rights to 瑞宁得 (阿那曲唑)和 Casodex (bicalutamide) in a number of European, African 和 other countries¹ 给juvis制药公司.

这些药物, used primarily to treat breast 和 prostate cancers, have lost their compound patent protection in these countries. 澳门在线赌城娱乐 already divested the rights to both 瑞宁得 和 Casodex 在2017年的美国.

Dave Fredrickson, Executive Vice President, 肿瘤学 Business Unit, said: “瑞宁得 和 Casodex are important established medicines 和 we are pleased that Juvisé Pharmaceuticals will now take on the work of making sure patients continue to have access to them. Today’s agreement is part of a broader strategy of reducing our portfolio of mature medicines to reallocate resources towards developing our pipeline of new medicines.”

金融方面的考虑

As there were no closing conditions to the divestment, the agreement became effective upon signing. Juvisé Pharmaceuticals has made an upfront payment of $181m to 澳门在线赌城娱乐 和 may also make future sales-contingent payments of up to $17m. Income arising from the upfront payment will be reported in 澳门在线赌城娱乐’s financial statements in the fourth quarter of 2019. Income from the upfront 和 any future payments will be reported within 其他 Operating Income & 费用. In 2018, 瑞宁得 had sales of $37m in the countries covered by this agreement, while Casodex 销售额达到2400万美元. The divestment does not change the Company’s financial guidance for 2019.

关于 瑞宁得

瑞宁得 (anastrozole) is an aromatase inhibitor, indicated primarily for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer 和 the treatment of advanced breast cancer in postmenopausal women with disease progression, 他莫昔芬治疗后.

关于 Casodex

Casodex (bicalutamide) is an 和rogen-receptor inhibitor, indicated for use in combination therapy with a luteinising hormone-releasing hormone analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.

关于澳门在线赌城娱乐

澳门在线赌城娱乐 (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development 和 commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - 肿瘤学, 心血管, 肾脏与代谢, 和呼吸. 澳门在线赌城娱乐 operates in over 100 countries 和 its innovative medicines are used by millions of patients worldwide. 请访问 澳门在线赌城娱乐.com 和 follow the Company on 推特 @澳门在线赌城娱乐.

联系人

参考文献

1. 为 瑞宁得 和 Casodex: Albania, Austria, Belgium, Bulgaria, Croatia, Cyprus, Estonia, Finl和, France, France exports², 德国, 希腊, 爱尔兰, 以色列, 意大利, 列支敦斯登, 卢森堡, 摩纳哥, 荷兰, 挪威, 罗马尼亚, 塞尔维亚, 斯洛文尼亚, 西班牙, 瑞典, 瑞士, 阿尔及利亚, 摩洛哥, 黎巴嫩, 突尼斯, 火鸡, 和 French-speaking Africa (Ivory Coast, 贝宁, 加蓬, 尼日尔, 毛利塔尼亚, 布吉纳法索, 马里, 乍得, 布隆迪, 喀麦隆, 几内亚, 塞内加尔, 中非共和国, 多哥, 吉布提, Democratic Republic of the Congo, Republic of the Congo 和 Madagascar). 此外,为 瑞宁得: Czech Republic, Hungary, Lithuania, Malta, Pol和 和 Portugal.
2. France exports are sales made in France, under the French entity of 澳门在线赌城娱乐, 出口至法国dom - tom (Départements d'outre-mer, Territoires d'outre-mer): DOM-TOMs are either ‘overseas collectives’ (administrative divisions of France) or ‘overseas departments’ (officially part of France), 包括:法属圭亚那, 法属波利尼西亚, 瓜德罗普岛, 马约特岛, 马提尼克岛, 新喀里多尼亚, La团聚, Saint-Barthelemy, 马尔丹街, Saint-Pierre-et-Miquelon 和 Wallis-et-Futuna.

艾德里安·坎普
公司秘书
澳门在线赌城娱乐